Under Health Secretary Robert F. Kennedy Jr., the Food and Drug Administration is moving forward with plans to ease access to unproven peptide drugs that are popular among members of Kennedy’s Make America Healthy Again movement—despite FDA staff scientists finding that the drugs have not been sufficiently studied to establish safety and efficacy and may cause harms.

The FDA submitted an “Interim Access Policy” on peptides for review by the White House, according to a filing notice posted on an Office of Management and Budget website. The posting does not provide information on the proposed policy. But people familiar with the proposal told The Associated Press that it would give the FDA “enforcement discretion” on certain peptide drugs. This would allow the agency to choose not to enforce current restrictions on peptides and provide an assurance to specialty pharmacies eager to start making them that they will not be targeted by the agency.

The Department of Health and Human Services, which oversees the FDA, did not respond to a request for comment from Ars Technica.

Read full article

Comments

An anonymous reader quotes a report from Reuters: Private credit’s expanding role in financing AI infrastructure faced one of its clearest market tests this week as CoreWeave’s bonds fell to distressed levels, raising questions about how lenders are pricing a boom built on chips, data centers and customer contracts. CoreWeave has about $50 billion of debt, according to LSEG data, making it one of the largest borrowers linking private credit to the AI buildout. The cost of insuring its debt against default climbed to about 1,200 basis points this week, while yields on some of its bonds rose to roughly 15% to 16%, signaling sharply increased investor concern over its credit risk. “There is still a price. Investors are still comfortable financing it, but they’re demanding more compensation for it,” said James Martin, senior US credit strategist at SMBC, referring to projects further from completion.

Carlyle estimates that private credit could finance roughly $1 trillion of the AI infrastructure buildout but warns that aggressive lending could create concentration risks similar to those seen in software lending. “The clearest lesson is not to avoid AI compute exposure, but to set concentration limits before the buildout accelerates further, not after,” Carlyle said.

Read more of this story at Slashdot.

OpenAI has updated its ChatGPT Chrome extension to let users access information from their open browser tabs. A demo video shows the new functionality in action. The Verge reports: It’s also updated ChatGPT in the sidebar, with the full power of ChatGPT and your entire conversation history in Chat or Work to use without leaving the page you’re viewing. It also enables ChatGPT Work to “control” your Chrome tabs for tasks like “sending messages, filling out forms, or downloading files,” similar to Google’s Gemini-powered “auto browse” feature, as well as organize or group open tabs.

Read more of this story at Slashdot.

Legal experts are sounding alarms that Meta will soon update its commercial terms to require business accounts to allow Meta to train AI on their linked website content, not just their social media posts.

Kicking in on October 30, the TOS update won’t allow businesses to opt out, instead suggesting that businesses stop using Meta services if they won’t agree to let Meta bots freely crawl their linked content.

As Nieman Lab reported Thursday, this will affect all business accounts but is particularly shocking for news publishers who could perhaps charge Meta millions in licensing fees to continually access their articles for AI training. Currently news organizations are fighting a battle with OpenAI over whether such training without licensing is fair use, and Meta’s terms seemingly risk granting it sweeping permissions, no matter which way the court leans.

Read full article

Comments